Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413038 | 0.95 | HRH3 (0.40) | HRH3AXLTYRO3MERTKTLR9 | |
| SCHEMBL5419614 | 0.86 | AXL (0.37) | HRH3AXLTYRO3MERTKTLR9 | |
| SCHEMBL5408718 | 0.86 | AXL (0.44) | HRH3AXLTYRO3MERTK | |
| SCHEMBL5414878 | 0.82 | AXL (0.45) | HRH3AXLTYRO3MERTKTLR9 | |
| SCHEMBL5412679 | 0.81 | HRH3 (0.47) | HRH3AXLTYRO3MERTK | |
| SCHEMBL5417439 | 0.81 | CYP4F2 (0.47) | AXLTYRO3MERTKTLR7 | |
| SCHEMBL5413298 | 0.81 | AXL (0.45) | HRH3AXLTYRO3MERTKTLR9 | |
| SCHEMBL5413106 | 0.80 | AXL (0.42) | AXLTYRO3MERTK | |
| SCHEMBL5401813 | 0.80 | AXL (0.43) | AXLTYRO3MERTKTLR9TLR8 | |
| SCHEMBL5410900 | 0.79 | AXL (0.43) | AXLTYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | HRH3 1124/4885AXL 1805/4885TYRO3 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.